Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 7068-7073

  Desjardins, Annick ^a   Reardon, David A ^a   Herndon II, James E ^a   Marcello, Jennifer ^a   Quinn, Jennifer A ^a   Rich, Jeremy N ^a   Sathornsumetee, Sith ^a   Gururangan, Sridharan ^a   Sampson, John ^a   Bailey, Leighann ^a   Bigner, Darell D ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; BRAIN TUMOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GLIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS;

EID: 58149231546     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0260     Document Type: Article

References (47)

1. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M. Radiotherapy for high-grade gliomas: does altered fractionation improve the outcome? Strahlenther Onkol 2004;180:401-7.
2. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
3. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
4. Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L. A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 1979;51:526- 32.
5. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients withnewly diagnosed high-grade glioma. Cancer 2001;92:420-33.
6. Prados MD, Larson DA, Lamborn K, et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 1998;40:57-63.
7. Gumerlock M, Neuwelt E. Principles of chemotherapy in brain neoplasia. In: Jellinger K, editior. Therapy of malignant brain tumors. New York: Springer-Verlag; 1987. p. 277-348.
8. Newton H, Turowski R, Stroup T, McCoy LK. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 1999;33:816-32.
9. Green S, Byar D, Walker M, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant gliomas. Cancer Treat Rep 1983;67:121-32.
10. See SJ, Gilbert MR. Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 2004;31:618-34.
11. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
12. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
13. Kleihues P, Cavenee WK. Pathology and Genetics Tumours of the Nervous System. Lyon: IARC Press; 2000. p. 314.
14. Reijneveld JC, Voest EE, Taphoorn MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 2000;247:597-608.
15. Chaudhry LH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409-15.
16. Ke LD, Shi YX, Im SA, Chen X, Yung WK. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity I human glioma cell lines. Clin Cancer Res 2000;6:2562-72.
17. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
18. Samoto K, Ikezaki K. Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascualarization in human brain tumors. Cancer Res 1995;55:1189-93.
19. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002;5:237-56.
20. Kim KJ, Li B. Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
21. Presta LG, Chen H. O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
22. Ferrara N, Hillan KJ. Gerber HP. Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non - small cell lung cancer. N Engl J Med 2006;355:2542-50.
25. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
26. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-25.
27. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003;97 (9 Suppl):2381-6.
28. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9.
29. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
30. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003;9:2940-9.
31. Reardon DA, Quinn JA, Rich JN, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005;104:1478-86.
32. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-38.
33. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
34. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
35. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients withm alignant glioma. J Neurosurg 2007;106:601-8.
36. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007;9:89-95.
37. Schwartz SG, Hickey M, Puliafito CA. Bilateral CRAO and CRVO from thrombotic thrombocytopenic purpura: OCT findings and treatment with triamcinolone acetonide and bevacizumab. Ophthalmic Surg Lasers Imaging 2006;37:420-2.
38. Frangié C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-8.
39. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8.
40. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
41. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide and glioblastoma. N Engl J Med 2005;352:997-1003.
42. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 2006;8:189-93.
43. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
44. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
45. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
46. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8.
47. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133 cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.